Cancer's ability to spread throughout the body often hinges on sophisticated molecular communication between tumor cells and their surrounding environment. This discovery reveals how gastric cancer cells exploit a specific signaling pathway to transform healthy tissue into a highway for metastasis, potentially opening new therapeutic avenues for one of the world's deadliest cancers.
Researchers engineered mouse models carrying gastric cancer mutations including Kras, Tgfbr2, and Trp53 alterations, then compared outcomes when Wnt1 protein expression was added. While mice with baseline mutations developed only gastric metaplasia, those expressing Wnt1 developed aggressive dysplastic tumors that successfully metastasized to the liver following experimental transplantation. The key mechanism involves tumor-secreted Wnt ligands partnering with TGFβ signaling to activate Has2 gene expression in cancer-associated fibroblasts, leading to massive hyaluronan accumulation in tissues surrounding metastatic sites. When researchers introduced hyaluronidase enzymes to break down this hyaluronan matrix, liver metastasis was dramatically suppressed.
This finding challenges the prevailing focus on blocking Wnt signaling within cancer cells themselves. Instead, it suggests targeting the supportive stromal environment may prove more effective against metastatic gastric cancer. Hyaluronan, normally present in modest amounts for tissue hydration and wound healing, becomes weaponized by cancer cells to create a permissive metastatic niche. The research provides compelling evidence that ligand-dependent Wnt signaling represents a distinct therapeutic target from the better-studied APC-mutated Wnt pathway. Given that gastric cancer ranks among the leading causes of cancer death globally, therapies targeting Has2 expression or hyaluronan degradation warrant rapid clinical investigation.